SCHEMBL29756181

SCHEMBL29756181

O=C(Cl)c1ccc(Br)c2ncnn12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
ALDH1A1 P00352 2/20 0.33
KDM4E B2RXH2 1/20 0.33
HTT P42858 1/20 0.33
GLA P06280 1/20 0.31
CHEK1 O14757 1/20 0.31
AURKA O14965 1/20 0.31
DAPK3 O43293 1/20 0.31
JAK2 O60674 1/20 0.31
MAP4K4 O95819 1/20 0.31
ABL1 P00519 1/20 0.31
NTRK1 P04629 1/20 0.31
LCK P06239 1/20 0.31
CSF1R P07333 1/20 0.31
RET P07949 1/20 0.31
MET P08581 1/20 0.31
PDGFRB P09619 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29756383 0.85 PDE4A (0.35) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL29756192 0.83 PDE4A (0.37) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL23030065 0.80 PDE4A (0.40) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL29756162 0.80 PDE4A (0.43) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL29756204 0.71 ALDH1A1 (0.35) ALDH1A1KDM4EHTTGLAKDR
SCHEMBL29756193 0.69 XDH (0.33)
SCHEMBL23030172 0.69 ALDH1A1 (0.36) ALDH1A1KDM4EKDR
SCHEMBL29756202 0.69 XDH (0.33)
SCHEMBL23030305 0.69 ACVRL1 (0.30)
SCHEMBL23029961 0.69 ALDH1A1 (0.36) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4293029-B1 AZAHETEROARYL COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF SHANGHAI BLUERAY BIOPHARMA CO LTD (CN) 2025-12-17 EP disclosed
US-20240182492-A1 AZAHETEROARYL COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) 2024-06-06 US disclosed
EP-4293029-A1 AZAHETEROARYL COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Shanghai Blueray Biopharma Co., Ltd. (CN) 2023-12-20 EP disclosed
WO-2022171166-A1 AZAHETEROARYL COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 上海青煜医药科技有限公司 2022-08-18 WO disclosed
CN-114907385-A Nitrogen heteroaryl compound, preparation method and application thereof 上海青煜医药科技有限公司 2022-08-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240182492-A1 AZAHETEROARYL COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF EZH2, EED, EZH1 PDE4A 3274/4885PDE4B 2882/4885PDE4C 3815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.